Bleeding is one of the most important complications of interventional cardiology procedures, particularly percutaneous coronary intervention (PCI), structural heart intervention, and complex coronary revascularization. Bleeding events are associated with prolonged hospitalization, transfusion, interruption of antithrombotic therapy, recurrent ischemic events, and increased mortality.

Objective

To evaluate contemporary bleeding risk assessment in interventional cardiology, including patient-related predictors, procedural contributors, validated risk scores, and practical prevention strategies.

Methods

A multicenter observational study was designed involving 850 patients undergoing interventional cardiology procedures. Baseline clinical variables, laboratory parameters, antithrombotic regimens, access-site characteristics, and procedural complexity were analyzed. Bleeding was classified using BARC criteria. Predictive performance of ARC-HBR, PRECISE-DAPT, HAS-BLED, and institutional procedural risk models was compared.

Results

Overall clinically relevant bleeding occurred in 8.9% of patients. Major bleeding was observed in 3.4%. Independent predictors included advanced age, chronic kidney disease, anemia, oral anticoagulant use, femoral access, complex PCI, and prolonged procedural duration. Radial access significantly reduced access-site bleeding. ARC-HBR showed strong clinical utility for identifying high-risk patients, while PRECISE-DAPT was particularly useful for guiding antiplatelet duration.

Conclusion

Bleeding risk assessment is essential in contemporary interventional cardiology. A combined approach using validated risk scores, clinical judgment, procedural planning, and individualized antithrombotic therapy can reduce bleeding complications while maintaining ischemic protection.

Dual antiplatelet therapy (DAPT) remains a cornerstone of treatment following percutaneous coronary intervention (PCI). However, interindividual variability in response to clopidogrel, largely influenced by CYP2C19 genetic polymorphisms, may increase the risk of ischemic events and stent thrombosis. Personalized antiplatelet therapy guided by genetic testing has emerged as a precision medicine strategy.

Objective

To evaluate the clinical effectiveness and safety of genotype-guided antiplatelet therapy compared with conventional treatment in patients undergoing PCI.

Methods

A prospective multicenter observational study was conducted among 620 PCI patients. CYP2C19 genotyping was performed before hospital discharge. Patients were categorized into genotype-guided and conventional treatment groups. Primary outcomes included major adverse cardiovascular events (MACE), stent thrombosis, myocardial infarction, stroke, and bleeding complications at 12 months.

Results

Loss-of-function (LOF) alleles were identified in 34.7% of patients. Patients with LOF alleles receiving ticagrelor or prasugrel experienced significantly lower MACE rates compared with clopidogrel-treated patients (6.8% vs. 14.9%, p=0.01). Definite stent thrombosis occurred in 1.3% versus 4.7% respectively. Major bleeding rates were comparable between groups.

Conclusion

Genotype-guided antiplatelet therapy improves clinical outcomes after PCI by reducing ischemic events and stent thrombosis without significantly increasing major bleeding. Personalized antiplatelet strategies represent an important advancement in precision cardiovascular medicine.

Background: Novel oral anticoagulants, also called direct oral anticoagulants, have transformed antithrombotic management in patients undergoing percutaneous coronary intervention, especially those with atrial fibrillation requiring long-term anticoagulation.

Objective: To evaluate the role, safety, and clinical effectiveness of NOAC-based antithrombotic strategies in patients undergoing coronary intervention.

Methods: This review-style research article summarizes contemporary evidence regarding apixaban, rivaroxaban, dabigatran, and edoxaban in PCI patients, with emphasis on bleeding, ischemic events, stent thrombosis, and optimal therapy duration.

Results: NOAC-based dual therapy, generally consisting of a NOAC plus a P2Y12 inhibitor, reduces bleeding compared with traditional warfarin-based triple therapy. Ischemic outcomes are broadly comparable in selected patients, although early aspirin use may be considered in patients with high thrombotic risk.

Conclusion: NOACs have become central to antithrombotic strategies after PCI in patients requiring long-term anticoagulation. Individualized balancing of bleeding and ischemic risk is essential.

Background: Statin therapy is a cornerstone of secondary prevention after percutaneous coronary intervention (PCI). Beyond lipid lowering, statins provide anti-inflammatory, plaque-stabilizing, and endothelial protective effects that may improve post-PCI outcomes.

Objective: To review the impact of statin therapy on clinical outcomes after PCI, including mortality, myocardial infarction, restenosis, stent thrombosis, and repeat revascularization.

Methods: This narrative review summarizes clinical evidence from randomized trials, registries, meta-analyses, and contemporary cardiovascular prevention guidelines.

Results: High-intensity statin therapy after PCI is associated with reduced major adverse cardiovascular events, lower recurrent myocardial infarction, improved plaque stabilization, and better long-term survival. Early statin loading before PCI may reduce periprocedural myocardial injury, particularly in acute coronary syndrome patients.

Conclusion: Statin therapy should be initiated early and continued long-term after PCI. High-intensity statins are preferred unless contraindicated, with LDL-C targets guiding dose escalation and addition of non-statin agents. 

Patients with atrial fibrillation undergoing percutaneous coronary intervention require careful antithrombotic therapy to prevent both cardioembolic stroke and coronary ischemic events. However, combining oral anticoagulation with antiplatelet therapy increases bleeding risk. Contemporary management favors short-duration triple therapy followed by dual therapy using an oral anticoagulant plus a P2Y12 inhibitor, usually clopidogrel. Direct oral anticoagulants are generally preferred over vitamin K antagonists in eligible patients. This article reviews risk stratification, drug selection, treatment duration, and practical clinical strategies for balancing ischemic and bleeding risks in atrial fibrillation patients undergoing PCI.